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Dr. Girgenrath discussed her data on 
MDC1A, which is a severe form of con-
genital muscular dystrophy character-
ized by hypotonia, muscle weakness, and 
premature death. MDC1A results from 
deficiency in the laminin alpha 2 chain of 
laminin-211, an extracellular matrix pro-
tein mainly found in skeletal muscle and 
Schwann cells. Defects in laminin-211 cause 
major disruption of structural stability and 
signal transduction that leads to apoptosis, 
failed regeneration, and chronic inflamma-
tion. An emerging idea in the study of mul-
tiple diseases is that different pathological 
processes are intimately connected and can 
even amplify one another; this theory may 
apply to MDC1A. Dr. Girgenrath presented 
data showing that while targeting regenera-
tion or apoptotic processes alone result in 
measurable improvement in the pathol-
ogy of MDC1A/DyW mice, a combinato-
rial therapeutic approach that targets both 
results in marked improvement in pathology 
with larger, more uniform myofiber size as 
well as improved regeneration and reduced 
fibrosis. Dr. Girgenrath’s results suggest that 
dual therapy has promising potential as an 
effective treatment for MDC1A.
Dr. Clemens showed her findings on 
NF-kappaB signaling in Duchenne muscular 
dystrophy (DMD). The chronic activation of 
NF-kappaB in dystrophic muscle leads to (1) 
infiltration of macrophages, (2) up-regula-
tion of the ubiquitin-proteasome system, 
and (3) down-regulation of the helix-loop-
helix muscle regulatory factor, MyoD. Dr. 
Clemens has characterized the role of A20 
(TNFAIP3), a critical negative regulator of 
NF-kappaB, in   muscle   regeneration. A20 
is highly expressed in regenerating mus-
cle fibers and knock down of A20 impairs 
muscle differentiation in vitro, suggesting 
that A20   expression is critically important 
region of PCG-1beta. Lastly, Dr. Guttridge 
revealed that activation of alternative signal-
ing during myogenesis is under the control of 
mTOR and that mTOR regulation of PCG-
1beta occurs through NF-kappaB.
Dr. Kumar described his findings show-
ing that the expression and activity of vari-
ous matrix metalloproteinases (MMPs) are 
dysregulated in skeletal muscle of dystro-
phin-deficient mdx mice. Treatment of mdx 
mice with Batimastat, a MMP inhibitory 
peptide, improved pathology and muscle 
contractile functions. Moreover, Dr. Kumar 
presented findings implicating MMP-9 as 
one of the most important MMPs involved 
in myofiber hypertrophy and necrosis, 
inflammation, and fibrosis in dystrophic 
muscle of mdx mice. Further, he also noted 
that increased levels of MMP-9 cause car-
diomyopathy in 1-year-old mdx mice.
Dr. Geisbrecht presented work on the sign-
aling and cell adhesive events that underlie 
defects in the formation and/or maintenance 
of the myotendinous junction (MTJ), which 
result in progressive myopathies in vertebrate 
models and humans. Dr. Giesbrecht’s labora-
tory uses the fruit fly, Drosophila melanogaster 
as a model to identify and characterize new 
genes required for proper MTJ formation. Her 
group identified Moleskin (Msk) as the ver-
tebrate ortholog of Importin-7. Loss of Msk 
function results in muscles that detach after 
muscle contraction begins. The canonical 
role of Importin-7/Msk is in nuclear import. 
However, in embryonic MTJ formation, Msk 
protein localizes to the sites of muscle-tendon 
attachment and is required for muscle to ten-
don signaling through the epidermal growth 
factor receptor signaling pathway to mediate 
stable formation of the MTJ. Future studies in 
the Geisbrecht laboratory will focus on Msk-
interacting proteins to further define how 
proteins are shuttled and retained at the MTJ.
Day 2 of the “Advances in Skeletal Muscle 
Biology in Health and Disease” conference 
consisted of 14 speakers across two ses-
sions – “Muscle diseases and regeneration” 
and “Clinical/translational research.” The 
synopsis below outlines some of the main 
findings and future directions presented in 
these two sessions.
Muscle diseases and 
regeneration
A major priority area in skeletal muscle 
research is that of muscle regeneration fol-
lowing damage or degenerative disease, or in 
the context of primary muscle myopathies. 
This first session on Day 2 of the symposium 
therefore highlighted the latest findings and 
future directions by scientists at the cutting 
edge of the muscle degeneration/regenera-
tion field including Drs. Denis Guttridge, 
Ashok Kumar, Da-Zhi Wang, Maury 
Swanson, Erika Geisbrecht, Sweta Girgenrath, 
and Paula Clemens. Dr. Guttridge presented 
new results specific to the alternative pathway 
of NF-kappaB. Earlier published data from 
the Guttridge laboratory using C2C12 cells 
showed that alternative NF-kappaB signaling 
is activated in late stage myogenesis and that 
this activation is associated with mitochon-
drial biogenesis. Dr. Guttridge presented new 
work, using both gain and loss of function 
components of the NF-kappaB alternative 
pathway, that regulation of mitochondrial 
biogenesis by alternative NF-kappaB occurs 
in vivo. In addition, he showed that this regu-
lation occurred through the transcriptional 
control of PCG-1beta, itself a well established 
regulator of mitochondria. During myo-
genesis, the RelB subunit of the alternative 
pathway binds to two enhancer sites in the 
first intron of PCG-1beta and this binding 
activates transcription through chroma-
tin modification in the proximal promoter 
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This is a very exciting time for researchers of 
adult skeletal muscle as we learn more about 
the incredibly plastic nature of skeletal muscle 
and begin to understand the signaling path-
ways regulating that plasticity. Moreover, the 
translation of skeletal muscle bench work to 
bedside is now an ongoing reality rather than 
just a buzz phrase. Despite this, adult skel-
etal muscle adaptations in health and disease 
have traditionally received largely peripheral 
attention in the context of both research 
and patient care. Therefore one of the pri-
mary purposes of this meeting was to bring 
together leading researchers that share a pas-
sion for adult skeletal muscle plasticity, with 
the aim of stimulating innovative and new 
directions that will advance this important 
field. We hope the interactive and friendly 
environment facilitated the attainment of 
this goal. Thanks to the efforts of the partici-
pants and organizers alike, we are confident 
that new collaborations will stem from, and 
ongoing collaborations were solidified at, this 
meeting. Finally, we expect this meeting will 
take place again in 2014 and hope it will be as 
fruitful and well-received as it was this year.
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Martin and his group examining the effects 
of inspiratory muscle strength training 
were reviewed. In this trial, patients who 
had received mechanical ventilation for 
approximately six continuous weeks were 
weaned at a greater rate following a spe-
cific inspiratory muscle strength training 
program, compared to a usual care group.
Dr. Durham presented data collected in 
collaboration with Dr. Melinda Sheffield-
Moore’s group. They found that skeletal 
muscle utilization of infused amino acids 
for protein synthesis is less efficient in older 
versus younger men following endurance-
type exercise. Despite reduced skeletal mus-
cle microvascular perfusion, this anabolic 
resistance was not due to reduced avail-
ability of amino acids for skeletal muscle 
protein synthesis, as circulating, interstitial, 
and intracellular amino acid concentrations 
were equal or higher in older men than in 
younger men. Markers of metabolic and 
oxidative stress as well as sarcolemmal dam-
age were greater in the older individuals, 
raising the possibility that hemodynamic 
effects on these variables may contribute to 
the observed age-related anabolic resistance.
Dr. Toth discussed his findings on myo-
sin myopathy of acute and chronic disease. 
With the development of chronic disease in 
humans, there are quantitative and quali-
tative changes in skeletal muscle myosin. 
These myosin phenotypes are evident 
functionally at the molecular and cellular 
level and may contribute to reduced whole 
muscle function. In this context, alterations 
in myosin content and functionality may 
represent a molecular mechanism whereby 
acute and chronic diseases impair skeletal 
muscle function and increase the risk for the 
development of physical disability.
The meeting concluded with a presenta-
tion from Dr. Byrne on his gene therapy 
work in Pompe disease. Pompe disease 
is an inherited condition of acid alpha-
glucosidase (GAA) deficiency resulting in 
lysosomal accumulation of glycogen in all 
tissues. This glycogen accumulation leads 
to muscle dysfunction and profound mus-
cle weakness, ultimately leading to cardi-
orespiratory failure. Dr. Byrne presented 
very encouraging pre-clinical and clinical 
findings from his laboratory showing that 
introduction of the normal GAA gene into 
muscle cells via gene therapy produces GAA 
protein at levels sufficient to reduce glyco-
gen accumulation and improve measures of 
respiratory function.
for regeneration of dystrophic muscle tis-
sue. Furthermore, down-regulation of the 
classical pathway of NF-kappaB activation 
is associated with up-regulation of the non-
classical pathway in regenerating muscle fib-
ers suggesting a mechanism by which A20 
promotes muscle regeneration. Dr. Clemens’ 
novel findings demonstrate the important 
role of A20 in muscle fiber repair and suggest 
the potential of A20 as a therapeutic target to 
ameliorate the pathology and clinical symp-
toms of DMD.
clinical/translational research
The final session covered bench to bed-
side translational research, presented by 
Drs. Marcas Bamman, Danny Martin, Bill 
Durham, Michael Toth, Hermien Kan, Glenn 
Walter, and Barry Byrne. Dr. Bamman dis-
cussed human muscle mass regulation with 
a focus on resistance training as the most 
readily available strategy to promote muscle 
regrowth following atrophy, but one that 
is not equally effective across individuals. 
He described the application of K-means 
cluster analysis to identify human responder 
phenotypes, which has led his laboratory to 
reveal a number of processes that appear 
to be integral to the myofiber hypertrophy 
adaptation in humans, including factors 
that promote protein synthesis and myonu-
clear addition. Dr. Bamman then described 
a reverse translational (“bedside to bench”) 
approach that his laboratory has utilized 
to test the impact of observations from the 
human cluster model via targeted genetic 
manipulation experiments of translational 
signaling proteins in vitro and in vivo (in 
mice). Lastly, Dr. Bamman described the 
power of this K-means clustering approach 
for discovery, presenting as yet unpublished 
findings from genomic microarrays and 
proteomic studies using 2D-DIGE.
Dr. Martin presented work on the 
effect of intraoperative hemidiaphragm 
stimulation on mitochondrial respiration 
in humans. Recent work in animals and 
humans has documented that the inac-
tive diaphragm undergoes rapid dysfunc-
tion including loss of contractile force 
and mitochondrial function. Dr Martin’s 
results show that electrically stimulating 
the human hemidiaphragm for 1 min 
every hour during cardiac surgery leads to 
improved state II and state IV mitochon-
drial respiration when compared to the 
unstimulated hemidiaphragm. The results 
of a recently published clinical trial by Dr. 
Judge et al.  Muscle pathophysiology and translated therapies
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